MedPath

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 2
Terminated
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Registration Number
NCT00554385
Lead Sponsor
Abbott
Brief Summary

The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in children with ADHD.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
283
Inclusion Criteria
  • The subject was randomized into Base Study (M06-888 or M10-345) and completed the Treatment Period.
  • If female, subject must be practicing at least one method of birth control throughout the study.
  • If female, the result of a pregnancy test is negative.
  • The subject is judged to be in generally good health.
Exclusion Criteria
  • The subject experienced a serious adverse event in Base Study (M06-888 or M10-345) that the investigator considered "possibly" or "probably related" to study drug.
  • The subject has taken any ADHD medication between the last dose of study drug in Study M06-888 or M10-345 and the first dose of study drug in the current study.
  • The subject has a positive urine drug screen for alcohol or drugs of abuse.
  • The subject anticipates a move outside the geographic area.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1ABT-089-
Primary Outcome Measures
NameTimeMethod
ADHD-RS-IV (HV)Day -1, Day 14, Months 1, 2, 3, 6, 9 & 12
CGI-ADHD-SDay -1, Day 14, Months 1, 2, 3, 6, 9 & 12
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (23)

Site Ref #/Investigator 6800

🇺🇸

Little Rock, Arkansas, United States

Site Ref #/Investigator 6812

🇺🇸

Boulder, Colorado, United States

Site Ref #/Investigator 8366

🇺🇸

Bradenton, Florida, United States

Site Ref #/Investigator 6808

🇺🇸

Jacksonville, Florida, United States

Site Ref #/Investigator 6827

🇺🇸

Orlando, Florida, United States

Site Ref #/Investigator 8383

🇺🇸

Libertyville, Illinois, United States

Site Ref #/Investigator 6802

🇺🇸

Northbrook, Illinois, United States

Site Ref #/Investigator 6824

🇺🇸

Overland Park, Kansas, United States

Site Ref #/Investigator 8428

🇺🇸

Troy, Michigan, United States

Site Ref #/Investigator 6902

🇺🇸

Omaha, Nebraska, United States

Scroll for more (13 remaining)
Site Ref #/Investigator 6800
🇺🇸Little Rock, Arkansas, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.